PMID- 31145896
OWN - NLM
STAT- MEDLINE
DCOM- 20191202
LR  - 20191202
IS  - 1873-3492 (Electronic)
IS  - 0009-8981 (Linking)
VI  - 495
DP  - 2019 Aug
TI  - CXC chemokine ligand 12 (CXCL12) in atherosclerosis: An underlying therapeutic 
      target.
PG  - 538-544
LID - S0009-8981(19)31884-4 [pii]
LID - 10.1016/j.cca.2019.05.022 [doi]
AB  - CXC chemokine ligand 12 (CXCL12) is a specific chemokine ligand and plays a 
      significant role in cell chemotaxis. Upon binding to CXC chemokine receptor 4 
      (CXCR4) or CXCR7, CXCL12 can activate different signaling cascades to regulate 
      cell proliferation, migration, and metabolism. CXCL12 exerts a pro-atherogenic 
      action by aggravating multiple pathogenesis of atherogenesis, including 
      dyslipidemia, inflammation, neointima hyperplasia, angiogenesis, and insulin 
      resistance. Serum CXCL12 levels are also markedly increased in patients with 
      atherosclerosis-associated disease. The present review focuses on recent advances 
      in CXCL12 research in the pathogenesis of atherosclerosis together with its 
      clinical values. This may provide insight into potential novel therapies for 
      atherosclerosis.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Gao, Jia-Hui
AU  - Gao JH
AD  - Institute of Cardiovascular Disease, Key Laboratory for Atherosclerology of Hunan 
      Province, Medical Research Experiment Center, Hunan Province Cooperative 
      Innovation Center for Molecular Target New Drug Study, University of South China, 
      Hengyang, Hunan 421001, China.
FAU - Yu, Xiao-Hua
AU  - Yu XH
AD  - Institute of Cardiovascular Disease, Key Laboratory for Atherosclerology of Hunan 
      Province, Medical Research Experiment Center, Hunan Province Cooperative 
      Innovation Center for Molecular Target New Drug Study, University of South China, 
      Hengyang, Hunan 421001, China.
FAU - Tang, Chao-Ke
AU  - Tang CK
AD  - Institute of Cardiovascular Disease, Key Laboratory for Atherosclerology of Hunan 
      Province, Medical Research Experiment Center, Hunan Province Cooperative 
      Innovation Center for Molecular Target New Drug Study, University of South China, 
      Hengyang, Hunan 421001, China. Electronic address: tangchaoke@qq.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190527
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
RN  - 0 (Chemokine CXCL12)
SB  - IM
MH  - Animals
MH  - Atherosclerosis/*drug therapy/*metabolism/pathology
MH  - Chemokine CXCL12/biosynthesis/*metabolism
MH  - Humans
MH  - Molecular Targeted Therapy/*methods
MH  - Signal Transduction/drug effects
OTO - NOTNLM
OT  - Atherosclerosis
OT  - CXCL12
OT  - CXCR4
OT  - CXCR7
EDAT- 2019/05/31 06:00
MHDA- 2019/12/04 06:00
CRDT- 2019/05/31 06:00
PHST- 2019/04/16 00:00 [received]
PHST- 2019/05/23 00:00 [revised]
PHST- 2019/05/24 00:00 [accepted]
PHST- 2019/05/31 06:00 [pubmed]
PHST- 2019/12/04 06:00 [medline]
PHST- 2019/05/31 06:00 [entrez]
AID - S0009-8981(19)31884-4 [pii]
AID - 10.1016/j.cca.2019.05.022 [doi]
PST - ppublish
SO  - Clin Chim Acta. 2019 Aug;495:538-544. doi: 10.1016/j.cca.2019.05.022. Epub 2019 
      May 27.